Mark A Espeland Selected Research

glimepiride (Amarel)

1/2021	Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
1/2021	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
11/2019	Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes.
9/2019	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
1/2018	Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
5/2015	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark A Espeland Research Topics

Disease

18	Dementia (Dementias) 11/2022 - 05/2003
17	Cognitive Dysfunction 01/2022 - 05/2003
16	Type 2 Diabetes Mellitus (MODY) 01/2022 - 06/2003
16	Weight Loss (Weight Reduction) 12/2020 - 02/2002
13	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2005
12	Hypertension (High Blood Pressure) 01/2022 - 10/2002
8	Overweight 01/2021 - 02/2002
5	Weight Gain 01/2022 - 06/2009
5	Inflammation (Inflammations) 11/2019 - 11/2008
4	Hearing Loss (Hearing Impairment) 01/2020 - 10/2003
3	Heart Failure 01/2022 - 07/2012
3	Frailty 01/2021 - 09/2017
3	Obesity 01/2021 - 04/2013
3	Atrophy 11/2020 - 12/2009
3	Alzheimer Disease (Alzheimer's Disease) 11/2020 - 01/2018
3	Insulin Resistance 10/2017 - 05/2013
3	Diabetes Mellitus 01/2016 - 04/2013
2	Stroke (Strokes) 01/2021 - 09/2019
2	Myocardial Infarction 01/2021 - 09/2019
2	Atherosclerosis 01/2020 - 11/2008
2	Chronic Disease (Chronic Diseases) 12/2018 - 09/2012
2	Neoplasms (Cancer) 12/2017 - 01/2007
2	Depressive Disorder (Melancholia) 07/2014 - 01/2011
2	Labyrinth Diseases 06/2009 - 10/2003
1	Macular Degeneration (Age-Related Maculopathy) 04/2022
1	Hypercholesterolemia 01/2022
1	Mental Disorders (Mental Disorder) 01/2022
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Morbid Obesity 01/2021
1	Body Weight (Weight, Body) 12/2020
1	Necrosis 11/2019
1	Pancreatitis 09/2019
1	Sleep Initiation and Maintenance Disorders (Insomnia) 03/2016
1	Breast Neoplasms (Breast Cancer) 01/2014
1	Wounds and Injuries (Trauma) 11/2011

Drug/Important Bio-Agent (IBA)

18	Hormones (Hormone)IBA 01/2022 - 01/2004
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2012
7	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 06/2003
7	Estrogens (Estrogen)FDA Link 12/2015 - 05/2003
6	glimepiride (Amarel)FDA LinkGeneric 01/2021 - 05/2015
6	Apolipoproteins E (ApoE)IBA 01/2021 - 11/2008
6	LinagliptinIBA 01/2021 - 05/2015
5	Fatty Acids (Saturated Fatty Acids)IBA 04/2022 - 09/2012
5	Insulin (Novolin)FDA Link 01/2022 - 06/2007
5	BuffersIBA 12/2020 - 01/2016
5	SodiumIBA 04/2013 - 02/2002
4	Triglycerides (Triacylglycerol)IBA 01/2022 - 10/2012
4	Conjugated (USP) Estrogens (Premarin)FDA Link 01/2020 - 12/2009
4	Antidepressive Agents (Antidepressants)IBA 07/2014 - 01/2011
3	Particulate MatterIBA 11/2022 - 01/2020
3	CalciumIBA 01/2020 - 08/2005
3	SteroidsIBA 05/2013 - 09/2005
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 04/2022 - 01/2020
2	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2021 - 01/2018
2	Blood Glucose (Blood Sugar)IBA 12/2020 - 01/2010
2	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 01/2020 - 02/2010
2	Interleukin-6 (Interleukin 6)IBA 11/2019 - 09/2017
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 09/2019 - 10/2009
2	Metformin (Glucophage)FDA LinkGeneric 12/2018 - 05/2015
2	ApolipoproteinsIBA 01/2018 - 03/2016
2	HDL CholesterolIBA 08/2016 - 10/2012
2	CholesterolIBA 05/2013 - 10/2004
2	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2009 - 10/2003
2	LipidsIBA 06/2007 - 10/2004
2	Progestins (Progestagens)IBA 05/2006 - 05/2003
1	Folic Acid (Vitamin M)FDA LinkGeneric 11/2022
1	Vitamin B Complex (B Vitamins)IBA 11/2022
1	Uric Acid (Urate)IBA 01/2022
1	omega-Chloroacetophenone (Mace)IBA 01/2021
1	Apolipoprotein E4IBA 01/2020
1	Endothelin-1 (Endothelin 1)IBA 11/2019
1	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 11/2019
1	C-Reactive ProteinIBA 11/2019
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2019
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2018
1	InterleukinsIBA 09/2017
1	Indicators and Reagents (Reagents)IBA 09/2017
1	Eicosapentaenoic AcidIBA 06/2017
1	Docosahexaenoic AcidsIBA 06/2017
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 06/2017
1	Caffeine (No Doz)FDA LinkGeneric 12/2016
1	Palmitic Acid (Hexadecanoic Acid)IBA 01/2016
1	Fatty Acid DesaturasesIBA 01/2016
1	Tamoxifen FDA LinkGeneric 01/2014
1	Raloxifene Hydrochloride (Evista)FDA Link 01/2014
1	Estradiol (Delestrogen)FDA LinkGeneric 05/2013
1	Sex Hormone-Binding GlobulinIBA 05/2013
1	Vitamin D FDA LinkGeneric 12/2012
1	Lipoproteins (Lipoprotein)IBA 10/2012
1	Hemoglobins (Hemoglobin)IBA 10/2012
1	Brain Natriuretic Peptide (Natrecor)FDA Link 07/2012
1	pro-brain natriuretic peptide (1-76)IBA 07/2012

Therapy/Procedure

24	Therapeutics 01/2022 - 10/2003
4	Caloric Restriction 01/2022 - 06/2013
3	Hysterectomy 11/2009 - 06/2004
2	Contraindications 01/2022 - 02/2011
2	Cognitive Training 05/2011 - 02/2011
1	Patient Readmission 01/2021
1	Ambulatory Care (Outpatient Care) 02/2012
1	Activities of Daily Living (ADL) 11/2011